<DOC>
	<DOCNO>NCT00002143</DOCNO>
	<brief_summary>To determine efficacy acitretin treatment psoriasis HIV/AIDS patient . Etretinate , retinoid , proven successful treatment HIV-infected patient psoriasis , elimination half-life 100 day . Acitretin , metabolite etretinate , much short half-life 2 3 day . Acitretin proven effective treat psoriasis patient without HIV infection reduce skin involvement clear condition , thoroughly evaluate HIV-infected patient .</brief_summary>
	<brief_title>Treatment Psoriasis Using Acitretin HIV-Positive Patients</brief_title>
	<detailed_description>Etretinate , retinoid , proven successful treatment HIV-infected patient psoriasis , elimination half-life 100 day . Acitretin , metabolite etretinate , much short half-life 2 3 day . Acitretin proven effective treat psoriasis patient without HIV infection reduce skin involvement clear condition , thoroughly evaluate HIV-infected patient . Patients receive acitretin daily , dose increase every 4 week base quantitative assessment skin use Psoriasis Area Severity Index ( PASI ) . Treatment continue total 20 week . Patients follow every 2 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Acitretin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Any nondermatologic medication . Patients must : HIV infection . Psoriasis involve least 10 percent body surface .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 1999</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Acitretin</keyword>
</DOC>